{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:21:44Z","timestamp":1762543304511,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012890","name":"Beijing Novartis Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.gendis.2025.101698","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T02:44:32Z","timestamp":1748400272000},"page":"101698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of the temporal distribution of anti-VEGF drugs in the retina and the correlation with the distribution of FcR isoforms"],"prefix":"10.1016","volume":"12","author":[{"given":"Jicai","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gendis.2025.101698_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/17512433.2014.884458","article-title":"Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF","volume":"7","author":"Stewart","year":"2014","journal-title":"Expet Rev Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101698_bib2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1097\/IAE.0b013e318134eecd","article-title":"Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits","volume":"27","author":"Gaudreault","year":"2007","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.gendis.2025.101698_bib3","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model","volume":"57","author":"Park","year":"2016","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.gendis.2025.101698_bib4","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.gendis.2025.101698_bib5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.3390\/jcm10112425","article-title":"Brolucizumab for choroidal neovascular membrane with pigment epithelial tear and subretinal fluid","volume":"10","author":"Bilgic","year":"2021","journal-title":"J Clin Med"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225001874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225001874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:15:26Z","timestamp":1762542926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225001874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2352304225001874"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101698","relation":{},"ISSN":["2352-3042"],"issn-type":[{"type":"print","value":"2352-3042"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of the temporal distribution of anti-VEGF drugs in the retina and the correlation with the distribution of FcR isoforms","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101698","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd\u00e9","name":"copyright","label":"Copyright"}],"article-number":"101698"}}